Loading...
Loading...
PRQR| Name | Value |
|---|---|
| Revenues | 6,336.9K |
| Cost of Revenue | 714.6K |
| Gross Profit | 5,622.3K |
| Operating Expense | 9,905.0K |
| Operating I/L | -3,775.0K |
| Other Income/Expense | 883.0K |
| Interest Income | 515.6K |
| Pretax | -2,892.0K |
| Income Tax Expense | -200.0K |
| Net Income/Loss | -2,692.0K |
ProQR Therapeutics N.V. is a biopharmaceutical company specializing in the discovery and development of RNA-based therapeutics for genetic disorders. Its primary products include sepofarsen, currently in phase II/III clinical trials for leber congenital amaurosis 10 disease, and ultevursen, in phase II/III clinical trials for USH2A-mediated retinitis pigmentosa and usher syndrome. The company also focuses on developing the Axiomer RNA base-editing platform technology. ProQR Therapeutics N.V. has license agreements with various institutions and companies, including Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as a collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders.
